Skip to main content

graft versus host disease Archives

Computer eyeballs graft-vs-host disease

Apr. 7, 2022—A machine learning algorithm identified areas of skin affected by chronic graft-versus-host disease on par with clinicians, opening the door to streamlining and standardizing this measure of patient response to therapy.

Read more


Treatment approved for patients with acute graft-versus-host disease

Jun. 13, 2019—The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC's Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.

Read more


Skin diseases study uses crowdsourcing to gather data

Feb. 21, 2019—In 1906, English statistician Francis Galton happened to visit a livestock fair where fairgoers were invited to guess the dressed weight of an ox scheduled for imminent slaughter. Some 800 attendees took part and afterwards Galton got hold of the contest data.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more